GlassScriptPhysician profile
Fariborz Ashtyani
NPI 1891762555
$4,608.96
in general payments reported to CMS, 2019-2025
15 companies · $670 in 2025
The $670 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $312 · 2020: $123 · 2021: $443 · 2022: $2,149 · 2023: $256 · 2024: $656 · 2025: $670.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,581.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Respicardia, INC. | $2,076.99 | 2021-2022 | |
| Inspire Medical Systems, INC. | $1,786.73 | 2019-2025 | Inspire |
| Glaxosmithkline, LLC. | $211.31 | 2024-2025 | Trelegy Ellipta, Nucala |
| Axsome Therapeutics, INC. | $102.43 | 2024-2025 | Sunosi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.95 | 2019-2025 | Jascayd |
| Harmony Biosciences LLC | $77.28 | 2024-2025 | |
| Baxter Healthcare | $71.73 | 2025 | Hillrom - Monarch Airway Clearance System |
| Astrazeneca Pharmaceuticals LP | $52.17 | 2025 | Breztri |
| Jazz Pharmaceuticals INC. | $48.13 | 2024-2025 | |
| 3b Medical, INC. | $22.73 | 2025 | Luna |
| Lilly USA, LLC | $19.35 | 2025 | Zepbound |
| Verona Pharma, INC. | $17.15 | 2025 | Ohtuvayre |
| Insmed, INC. | $17.00 | 2024 | Arikayce |
| Avadel Cns Pharmaceuticals, LLC | $14.69 | 2025 | Lumryz |
| Xeris Pharmaceuticals, INC. | $13.32 | 2024 | Keveyis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fariborz Ashtyani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.